Samsung Bioepis Gets Canadian Trastuzumab Nod

Ontruzant Biosimilar Rival To Herceptin To Be Marketed By Organon In Canada

 
• By Dave Wallace

Samsung Bioepis has received approval from Health Canada for its Ontruzant trastuzumab biosimilar rival to Herceptin in 150mg single-use and 440mg multi-dose vials. The product will be marketed in Canada by Organon.

Canada Crowd Flags
Samsung Bioepis is celebrating approval for Ontruzant – but Canada’s biosimilar trastuzumab market is becoming crowded • Source: Rawpixel Ltd / Alamy Stock Photo

More from Products

More from Generics Bulletin